Back to NAMS Overview
NGM · Valuation Lab
NAMS
NewAmsterdam Pharma Company N.V.
Last$27.42
Market cap3.2B
EV/EBITDA-12.0x
Intrinsic value
$6.26
MoS -338.2% · Overvalued
Assuming 15.0% FCF margin and 2.1% Y1–5 growth.
Upside to price
EV (DCF)95.5M
Terminal share71%
Expected IV$6.25
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 71% of EV
PV of stage FCFs27.7M
PV of terminal value67.8M
Enterprise value95.5M
Net cash / (debt)636.1M
Equity value731.6M
Intrinsic value / share$6.26
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 23M | 3.5M | 3.3M | 94.3% |
| Y2 | 23.5M | 3.5M | 3.1M | 89.0% |
| Y3 | 24M | 3.6M | 3M | 84.0% |
| Y4 | 24.5M | 3.7M | 2.9M | 79.2% |
| Y5 | 25M | 3.8M | 2.8M | 74.7% |
| Y6 | 25.5M | 3.8M | 2.7M | 70.5% |
| Y7 | 26M | 3.9M | 2.6M | 66.5% |
| Y8 | 26.6M | 4M | 2.5M | 62.7% |
| Y9 | 27.1M | 4.1M | 2.4M | 59.2% |
| Y10 | 27.6M | 4.1M | 2.3M | 55.8% |
| Terminal | — | — | 67.8M | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.